Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Inactive
Last updated: April 9, 2025
Vaginal Tablet with Adhesive Microcapsules
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Texas Health Science Center at San Antonio, University of Oslo, University of Tromso
Inactive
Last updated: April 9, 2025
UPA Vaginal Ring
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Short-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): Population Council, HRA Pharma
Inactive
Last updated: April 9, 2025
Uniplant
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Long-Acting
  • Development Stage: Phase III
  • Developer(s)/Researcher(s): Population Council, Theramex, University of Bahia
Inactive
Last updated: April 9, 2025
TU + ENG

Testosterone Undecanoate (TU) + Etonogestrel (ENG)

  • User: Male
  • Hormonal: Hormonal
  • Delivery Type: Multiple
  • Intended Duration: Short-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): Organon
Active
Last updated: April 9, 2025
Trimegestone Ring

TMG + Estriol Ring

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Short-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Evestra, Dinox, University of Campinas (UNICAMP), SocraTec R&D GmbH
Inactive
Last updated: April 9, 2025
Testosterone Undecanoate (TU)

TU, Aveed

  • User: Male
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Phase III
  • Developer(s)/Researcher(s): Bayer, National Research Institute for Family Planning in Beijing
Inactive
Last updated: April 9, 2025
Tanaproget

NSP-989, NSP-989 COMBO, Tanaproget COMBO, WAY-166989

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Short-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): Wyeth Research, Ligand Pharmaceuticals, Inc.
Active
Last updated: April 9, 2025
Self-Aggregating Injectable Microcrystals
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Not Yet Determined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Massachusetts Institute of Technology
Inactive
Last updated: April 9, 2025
SAVVY Vaginal Gel

C31G Vaginal Gel

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Phase III
  • Developer(s)/Researcher(s): Adamis Pharmaceuticals/BioSyn, FHI 360
Inactive
Last updated: April 9, 2025
Reservoir-Type LNG Delivery System
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Tehran University